Primovax” – A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-resectable Pancreatic Cancer.

Pharmexa A/S0 个研究点目标入组 520 人开始时间: 2006年2月16日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1. Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic adenocarcinoma of the pancreas.
•2. Adequate haematological parameters.
•3. Adequate baseline liver functions.
•4. Serum creatinine equal to or less than 1.5 mg/dL
•5. Performance status ECOG 0-1.
•6. Male or female 18-75 years inclusive.
•7. Minimum life expectancy of 3 months.
•8. Written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Treatment with chemotherapy for pancreatic cancer.
•2. Treatment with other investigational drugs within the last 4 weeks prior to inclusion.
•3. Immune-suppressive therapy < 4 weeks prior to inclusion.
•4. Chronic corticosteroid use except for asthma inhalers/topical use.
•5. Radiotherapy within 8 weeks of randomisation.
•6. Other prior malignancies except for adequately treated non-melanoma skin cancers (BCC, SCC) and carcinoma in situ of the cervix.
•7. Known diagnosis of HIV (AIDS), Hepatitis B, C.
•8. Known history of or co-existing autoimmune disease.
•9. Known CNS metastases.
•10. Clinically significant serious disease or organ system disease not currently controlled on present therapy.
•11. Pregnancy or lactation.
•12. Women of childbearing potential not using reliable and adequate contraceptive methods.
•13. Known sensitivity to any components of vaccine, gemcitabine or GM-CSF.
•14. Unable for any other reason to comply with the protocol (treatment or assessments).

发起方